Evidence map›Paper›PMID 31997116›Full record

ArticleThe patient2020

A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective.

Edouard Louis, Juan M Ramos-Goñi, Jesus Cuervo, Uri Kopylov, Manuel Barreiro-de Acosta, Sara McCartney, Greg Rosenfeld, Dominik Bettenworth, Ailsa Hart, Kerri Novak and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in The patient, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 4 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Psychometric evaluation of the Functional Assessment of chronic illness therapy-fatigue (FACIT-Fatigue) in adults with moderately to severely active Crohn's disease.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 6 countries.

Edouard LouisCHU de Liège et Université de Liège, Domaine du Sart Tilman, 4000, Liège, Belgium. edouard.louis@uliege.be.
Juan M Ramos-GoñiAxentiva Solutions, Calle el Calvario, 38107, Tacoronte, Santa Cruz de Tenerife, Spain.
Jesus CuervoAxentiva Solutions, Calle el Calvario, 38107, Tacoronte, Santa Cruz de Tenerife, Spain.
Uri KopylovSheba Medical Center, Ramat Gan, Israel.
Manuel Barreiro-de AcostaComplejo Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
Sara McCartneyUniversity College London Hospitals, London, UK.
Greg RosenfeldUniversity of British Columbia, 770-1190 Hornby St., Vancouver, BC, V3K 3V9, Canada.ORCID 0000-0002-4951-8818
Dominik BettenworthDepartment of Medicine B, Gastroenterology and Hepatologie, University Hospital Munster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.ORCID 0000-0002-1435-4825
Ailsa HartLondon North West Healthcare, London, UK.
Kerri NovakThe University of Calgary, 3280 Hospital Drive NW, Calgary, AB, T2N4N1C, Canada.
Xavier DonnetAssociation Crohn-RCUH, 2 Rue des Argentines, 6110, Montigny-le-Tilleul, Belgium.
David EastonCanada Crohn's and Colitis, Canada, 220 Stiver St., Russell, ON, K4R 1G9, Canada.
Roberto SaldañaConfederación de Asociaciones de Enfermos de Crohn y Colitis Ulcerosa de España, Madrid, Spain.
Katja Protze, Schneebergstraße 33, 01277, Dresden, Germany.
Eyal TzurCrohn's and Colitis Foundation of Israel, Hod Hasharon Towers, 4 Hacharash St., Neve Ne'eman, 4524075, Hod Hasharon, Israel.
Gabriela AlperovichAbbVie Inc., Av. Burgos 91, 28050, Madrid, Spain.
Francesc CasellasCrohn-Colitis Care Unit (UACC), Hospital Universitari Vall d'Hebron-Pso, Vall d'Hebron 119, Barcelona, 08035, Spain.
AbbVie (Spain) · ESAsociación Española Contra el Cáncer · ESCenter for Systems Biology Dresden · DEComplejo Hospitalario Universitario de Santiago · ESCrohn's and Colitis Canada · CALondon North West Healthcare NHS Trust · GBRoyal London Hospital · GBTel Aviv University · ILUniversity Hospital Münster · DEUniversity of British Columbia · CAUniversity of Calgary · CAUniversity of Liège · BEVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCrohn's disease (CD) and ulcerative colitis (UC) are chronic, inflammatory bowel diseases (IBD). Each class and type of medication available for the treatment of IBD has distinct characteristics and long-term effects that a patient may consider. We present the results of qualitative research that aimed to develop a descriptive framework that outlines the most relevant disease and/or treatment attributes for IBD treatment decisions and focuses on the patient perspective.

methodsThis research employed a three-step approach: a literature review to identify a broad list of attributes, a focus group meeting including patients and clinicians to assess the relevance of the attributes, and two rounds of voting to name and define each attribute. The literature review was used to develop the initial list of attributes. Although the same attributes were defined for both UC and CD, the relative importance of each attribute to UC or CD was considered. The list of attributes was discussed and evaluated in the focus group meeting, which included eight patient representatives and nine gastroenterologists. Using feedback elicited from the focus group meeting, the research team developed a draft of the descriptive framework that grouped the attributes into domain subsets. All members of the focus group participated in two subsequent rounds of structured, online voting, which was used to refine the wording to name and define each attribute. Additionally, participants ranked all the attributes included in the descriptive framework to suggest which attributes were less relevant and could be omitted.

resultsAmong 574 publications retrieved from the databases and registries, we identified 32 eligible publications, and an initial list of attributes was developed. This list was refined during the focus group meeting, resulting in a draft descriptive framework of attributes within subsets of domains. The final descriptive framework was developed based on structured rounds of online voting to further refine attribute names and definitions. In the final descriptive framework, a total of ten attributes were identified: abdominal pain, other disease-related pain, bowel urgency, fatigue, risk of cancer and serious infections within the next 10 years, risk of mild to moderate complications, aesthetic complications related to treatment, emotional status, sexual life, and social life and relationships. These attributes were distributed across three domains: efficacy, complications and risk, and health-related quality of life.

conclusionsThrough the identification of the ten most relevant attributes that influence patient decision making for IBD treatments, we developed a descriptive framework that should be considered by physicians when discussing IBD treatment options with their patients. The results of our qualitative research may also be helpful for the development of future IBD clinical studies and quantitative research.

Indexed as

Drug-Related Side Effects and Adverse ReactionsFocus GroupsGermanyHumansInflammatory Bowel DiseasesPatientsQualitative Research

Identifiers

PMID31997116
PMCPMC7210247
OpenAlexW3003606873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.